Management of Increased Albumin-to-Creatinine Ratio with Normal eGFR

Understanding the Clinical Significance

An elevated albumin-to-creatinine ratio (ACR) with normal estimated glomerular filtration rate (eGFR) represents early kidney damage and is associated with increased risk for progression to more advanced kidney disease and cardiovascular events, according to the American Diabetes Association, even before GFR decline occurs 1, 2
This condition is classified as Stage 1 or 2 chronic kidney disease (depending on exact eGFR value) with albuminuria category A2 (30-299 mg/g) or A3 (≥300 mg/g), as defined by the American College of Physicians 3, 2

Confirm persistent albuminuria with 2-3 specimens collected over a 3-6 month period due to biological variability of >20% between measurements, as recommended by the American Diabetes Association 2
Rule out factors that can transiently elevate ACR: exercise within 24 hours, infection, fever, congestive heart failure, marked hyperglycemia, menstruation, and marked hypertension, according to the American Heart Association 2
Assess for other risk factors that may accelerate kidney disease progression: hypertension, diabetes, smoking, obesity, dyslipidemia, as suggested by the American College of Physicians 3

For ACR 30-299 mg/g: Initiate ACE inhibitor or ARB therapy (Grade B recommendation) to reduce the risk of chronic kidney disease progression and cardiovascular events, as recommended by the American Diabetes Association 1, 4
For ACR ≥300 mg/g: Strongly recommended to initiate ACE inhibitor or ARB therapy (Grade A recommendation) to reduce the risk of chronic kidney disease progression and cardiovascular events, according to the American Heart Association 1, 4
Titrate to maximum tolerated dose for optimal albuminuria reduction, as suggested by the American Diabetes Association 5

Target blood pressure <140/90 mmHg for those with ACR <30 mg/g, as recommended by the American College of Physicians 3
Consider more intensive target of <130/80 mmHg for those with ACR ≥30 mg/g, according to the American Heart Association 3
Optimize blood pressure control to reduce risk of CKD progression, as suggested by the American Diabetes Association 1, 2

Optimize glycemic control to reduce risk of CKD progression, according to the American Diabetes Association 1, 2
Consider SGLT2 inhibitors in patients with type 2 diabetes and ACR ≥30 mg/g for additional kidney protection, even with normal eGFR, as recommended by the American Diabetes Association 5

Monitor serum creatinine and potassium levels after initiating ACE inhibitors or ARBs, as suggested by the American Heart Association 4, 2
Expect a small rise in serum creatinine (up to 30%) which is generally acceptable; larger increases warrant further investigation, according to the American College of Physicians 4
Follow ACR and eGFR at least annually to assess treatment response and disease progression, as recommended by the American Diabetes Association 1, 3

ACE inhibitors or ARBs are not recommended for primary prevention in patients with normal blood pressure and normal ACR (<30 mg/g), according to the American Heart Association 7, 2
Avoid ACE inhibitors and ARBs during pregnancy, as recommended by the American College of Obstetricians and Gynecologists 4
Patients with diabetes should be screened annually for albuminuria regardless of eGFR, according to the American Diabetes Association 1, 6

Consider referral to nephrology for uncertainty about etiology of kidney disease, rapidly increasing albuminuria despite treatment, difficult management issues, or if eGFR declines to <30 mL/min/1.73 m², as suggested by the American Society of Nephrology 2, 4